ReviewBlood research2025
Treatment of transplant-ineligible multiple myeloma.
Review in Blood research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Economic advantage of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: A cost-per-responder evaluation.Journal of managed care & specialty pharmacy · 2026Trial
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment landscape for patients with multiple myeloma (MM) who are ineligible for transplant has evolved significantly over time. Initially dominated by melphalan-based regimens, treatment options have progressed with the introduction of proteasome inhibitors, immunomodulatory drugs, and more recently, anti-CD38 monoclonal antibodies. These advances have led to the development of doublet, triplet, and quadruple regimens, aiming not only for survival benefits, but also for meaningful responses, as represented by minimal residual disease negativity, while maintaining tolerability. The management of frailty in older patients has gained importance, and various frailty assessment tools have been proposed to guide treatment decisions. At the same time, ongoing efforts are being made to develop differentiated treatment strategies for patients with frailty based on frailty status. This review discusses the key therapeutic strategies for patients with MM who are transplant ineligible, the role of frailty assessments, and emerging treatment strategies that promise further evolution in treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.